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Introduction {#sec1}
============

The adipocyte-enriched yellow bone marrow develops during aging and obesity, and it may contribute to a dysfunction of the osteogenic and hematopoietic niches of long bones. According to recent data, increased marrow adipose tissue (MAT) in obese individuals is correlated with osteoporosis and increased fracture risk ([@bib12], [@bib44]). Similarly, type II diabetes has been linked to reduced bone quality ([@bib5]). However, a causal relationship has not been fully established, as mice fed a high-fat diet also showed a rapid increase in MAT while bone parameters remained unaffected ([@bib10]). Nevertheless, marrow adipogenesis is associated with impaired hematopoiesis ([@bib38]). Several seemingly opposing influences, such as aging and obesity but also caloric restriction and anorexia, irradiation therapy, thiazolidinediones, and glucocorticoids, promote the accumulation of MAT ([@bib8]). Two types of MAT have been described: the constitutive MAT (cMAT), localized around the growth plates, and regulated MAT (rMAT), which accumulates later in life and in response to high-fat feeding ([@bib42]).

It has been proposed that MAT progenitors are radio-resistant, non-hematopoietic cells with a mesenchymal origin ([@bib3]). Mesenchymal stromal cells (MSCs) are capable of giving rise to osteoblasts, chondroblasts, and adipocytes ([@bib14]). Lineage tracing has linked the developmental origin of MSCs to Osterix1 (Osx1)-expressing cells in neonatal bone marrow ([@bib32]) and to cells expressing Leptin receptor (LepR) in adult bone marrow ([@bib52]). Concomitantly, Leptin signaling regulates MAT formation and osteogenesis in adult mice ([@bib51]). Subsets of bone marrow MSCs, such as C-X-C motif chemokine (CXCL)12-abundant reticular (CAR) cells, provide essential maintenance signals for the hematopoietic stem cell niche ([@bib30], [@bib36]).

The involvement of MAT in local osteogenic and immunomodulatory processes as well as systemic metabolism emphasizes the necessity to further investigate the adipogenic potential of bone marrow mesenchymal cells. Using a combination of flow cytometry and genetic lineage tracing, we delineate considerable cellular heterogeneities, and we identify distinct subsets of mesenchymal cells within the bone marrow cavity of the long bones in male mice. Specifically, we describe a multipotent population with stem cell-like properties residing within the perivascular niche that gives rise to unilaterally committed sub-populations of osteochondrogenic and adipogenic lineages under in vitro and in vivo conditions. Adipocytic cells significantly impair hematopoietic repopulation and bone fracture healing. This latter effect is mediated by secreted Dipeptidyl peptidase-4 (DPP4), an important target of anti-diabetes treatments ([@bib25], [@bib29]). These findings altogether support the hypothesis of a deteriorative role of MAT in bone health and hematopoiesis.

Results {#sec2}
=======

Identification of the Bone Adipocytic Lineage {#sec2.1}
---------------------------------------------

To delineate the heterogeneous composition of the mesenchymal lineage of the bone, we used flow cytometry as reported in adipose tissues and bone ([@bib34], [@bib40], [@bib43], [@bib48]). To this end, we isolated distinct populations of non-hematopoietic (Cluster of differentiation \[CD\]45^−^), non-endothelial (CD31^−^) cells that could be subdivided by expression of Stem cell antigen (Sca)1 into two subsets of culture-adherent fibroblasts also expressing the surface receptor platelet-derived growth factor-α (Pα; [Figures 1](#fig1){ref-type="fig"}A and [S1](#mmc1){ref-type="supplementary-material"}A--S1C). During in vitro differentiation, CD45^−^CD31^−^Sca1^+^ cells exhibited a highly adipogenic but limited osteochondrogenic potential. CD45^−^CD31^−^Sca1^−^ cells, in turn, were non-adipogenic but markedly osteochondrogenic ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Bone Marrow-Resident Mesenchymal Cells Display Functional Heterogeneity(A and B) Flow cytometric separation of CD31^−^CD45^−^ cells by Sca1 selection, followed by (B) Oil Red O (adipogenesis), Alizarin Red S (osteogenesis), and Alcian Blue (chondrogenesis) staining of Sca1^+^ and Sca1^−^ cells differentiated under the corresponding conditions.(C and D) FACS analyses (as in A) of CD31^−^CD45^−^Sca1^+^ cells separated by CD24 expression, and (D) subsequent differentiation of cells (as in B).(E) Representative image of clonal analysis with feeder cells by co-staining of clone 19-derived tdTomato^+^ cells with Perilipin, Osteocalcin, or Aggrecan to show lineage-specific differentiation potential.(F) In vivo luciferase imaging (top panels) and macroscopic identification (arrows; lower panels) of transplants 8 weeks after sternal subcutaneous (s.c.) injection of the indicated cell populations isolated from rep^AdiLuc^ mice.(G) Microscopy of corresponding Movat-Pentachrome stains (yellow, mineralized structure; blue, cartilage; purple, nuclei. Scale bars, 30 μm.See also [Figures S1--S3](#mmc1){ref-type="supplementary-material"} and [Tables S1--S4](#mmc1){ref-type="supplementary-material"}.

Consistent with white adipose tissue ([@bib2], [@bib40]), we isolated a population of unilaterally committed adipogenic progenitors that was CD45^−^CD31^−^Sca1^+^CD24^−^ and a CD45^−^CD31^−^Sca1^+^CD24^+^ population that displayed tri-lineage differentiation potentials ([Figures 1](#fig1){ref-type="fig"}C and 1D). Colony-forming unit (CFU-F) potentials and in vitro recovery rates were highest in fibroblastic cells expressing Sca1 and/or Pα and were highest in the CD45^−^CD31^−^Sca1^+^Pa^+^CD24^+^ subset ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). CFU-F potential was enriched in the osteogenic CD45^−^CD31^−^Sca1^−^Pα^+^ population but absent in CD45^−^CD31^−^Sca1^−^Pα^−^ cells. Separation of the osteogenic CD45^−^CD31^−^Sca1^−^Pα^+^ population by CD24 expression was also possible, but these subsets showed identical differentiation capacities ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). Similarly, the CD45^−^CD31^−^Pα^−^Sca1^−^ cells were mostly CD24^+^ but were non-CFU-F ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1H). Importantly, two separate clonal analyses of the tri-potent CD45^−^CD31^−^Sca1^+^CD24^+^ population revealed a marked homogeneity of a multipotent phenotype, where 64 of 68 (94%) and 45 of 54 (83%) clones were able to differentiate into all three lineages when cultivated in the presence or without supporting feeder cells, respectively ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}I; [Table S1](#mmc1){ref-type="supplementary-material"}). The somewhat lower homogeneity in the feeder-free assay could be due to technical differences, such as replicative senescence, but it could also mean that this population relies on exposure to trophic signals from the microenvironment to retain long-term multipotency.

The transcription factor zinc-finger protein (Zfp)423 labels adipogenic cells in white adipose tissue (WAT) ([@bib18]). Surprisingly, but consistent with the initial report using a *Zfp423*-driven EGFP reporter strain (*Zfp423-*EGFP), *Zfp423*-EGFP^+^ (Zfp423^+^) cells occurred as a small sub-population of \<1% within the CD45^−^CD31^−^Sca1^−^ population, while all adipogenic CD45^−^CD31^−^Sca1^+^ cells were GFP^−^ ([Figure S1](#mmc1){ref-type="supplementary-material"}J). This small subset of adipogenic cells was likely not initially detected due to a dilution effect within the strongly osteochondrogenic cell fraction ([Figure 1](#fig1){ref-type="fig"}B). In culture, CD45^−^CD31^−^Sca1^−^Zfp423^+^ cells maintained GFP expression before and after differentiation into adipocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}K). In contrast, all CD45^−^CD31^−^Sca1^+^ cells uniformly acquired GFP expression only during differentiation, a process that correlated with a concomitant loss of Sca1 expression ([Figures S1](#mmc1){ref-type="supplementary-material"}K--S1N).

In *Pα*-EGFP reporter mice, multipotent cells and osteogenic progenitors were more abundant in the metaphysis compared to the diaphysis, whereas adipogenic progenitors were evenly distributed. Further analyses of Pα, Sca1, and CD24 expression localized osteogenic progenitors to the endosteum. The majority of multipotent and adipogenic progenitors cells resided in a non-endosteal localization within 40 μm of the bone surface, and it revealed a perivascular association of all non-endosteal Pα^+^ cells to blood vessels of \<10 μm in diameter ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2E). These findings suggest different micro-anatomical localizations of these functionally distinct cell populations and a preferential association of perivascular multipotent and adipogenic cells to L type vessels, while the distribution of endosteal osteogenic cells resembles more closely localizations of H type endothelium ([@bib20], [@bib24]). Consistent with the preferential occurrence of adipocytes in the bone tips of young mice, Zfp423^+^ cells mainly localized to metaphyseal regions of the bone, and they labeled a subset of blood vessel-associated progenitors alongside all mature adipocytes of the marrow cavity ([Figures S2](#mmc1){ref-type="supplementary-material"}F--S2H).

Together, these findings indicate the presence of at least four distinct cell populations in defined micro-anatomies within the bone: a tri-potent, perivascular population with stem cell-like characteristics (CD45^−^CD31^−^Sca1^+^CD24^+^), two functionally and anatomically distinct progenitor populations that are fate-committed toward either the osteochondrogenic (CD45^−^CD31^−^Sca1^−^Pα^+^) or adipogenic (CD45^−^CD31^−^Sca1^+^CD24^−^) lineages, and a more mature CD45^−^CD31^−^Sca1^−^Zfp423^+^ adipocyte precursor stage. All four populations were present in different bone compartments ([Table S2](#mmc1){ref-type="supplementary-material"}) and all CD45^−^CD31^−^Sca1^+^ cells were adipogenic ([Figure S2](#mmc1){ref-type="supplementary-material"}I). No correlations between MAT occurrence and cell frequencies were evident, and we conclude that regulatory signals, such as leptin, may determine the progression into mature adipocytes. Since Sca1^+^ adipogenic progenitors are also more evenly distributed compared to mature Zfp423^+^ cells ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2H), this implies that signals preventing adipogenic maturation could be differentially distributed within the bones of young mice.

To test in vivo differentiation potentials, we generated a triple-transgenic mouse strain carrying alleles of the *Zfp423*-EGFP reporter, Adiponectin (*Adipoq*)-Cre, and a luciferase reporter within the Rosa26 locus that is only expressed after Cre-mediated recombination, e.g., in mature adipocytes (rep^AdiLuc^, [Figure S2](#mmc1){ref-type="supplementary-material"}J), and we generated a second strain with constitutive red fluorescence (mTmG reporter allele) crossed to the *Zfp423*-EGFP reporter (rep^tdTom^; [Figure S2](#mmc1){ref-type="supplementary-material"}K). Fresh cells of all four populations isolated from rep^AdiLuc^ or rep^tdTom^ by fluorescence-activated cell sorting (FACS) ([Figure S2](#mmc1){ref-type="supplementary-material"}L) were transplanted into the sternal region of B6/Albino mice. After 8 weeks, in vivo imaging of luciferase and Perilipin immunofluorescence (IF) showed that transplants of the CD45^−^CD31^−^Sca1^+^CD24^−^ and CD45^−^CD31^−^Sca1^−^Zfp423^+^ adipogenic populations consistently gave rise to bona fide mature adipocytes, while in vitro osteogenic CD45^−^CD31^−^Sca1^−^Pα^+^ cells did not ([Figures 1](#fig1){ref-type="fig"}F, 1G, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Interestingly, CD45^−^CD31^−^Sca1^+^CD24^+^ cells gave rise to luciferase-positive and -negative transplants ([Figure 1](#fig1){ref-type="fig"}F). Movat-Pentachrome staining of luciferase-negative tissues of CD45^−^CD31^−^Sca1^+^CD24^+^ and CD45^−^CD31^−^Sca1^−^Pα^+^ cells revealed bone-like osteochondrogenic/mineralized structures but never adipocytes ([Figures 1](#fig1){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}C). Consistent with this observation, intratibial injections of the four cell populations showed that only CD45^−^CD31^−^Sca1^+^CD24^+^, CD45^−^CD31^−^Sca1^+^CD24^−^, and CD45^−^CD31^−^Sca1^−^Zfp423^+^ cells, but never CD45^−^CD31^−^Sca1^−^Pα^+^, gave rise to Zfp423^+^ adipogenic cells in their endogenous microenvironment ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Moreover, only CD45^−^CD31^−^Sca1^+^CD24^+^ transplants were able to give rise to adipogenic CD45^−^CD31^−^Sca1^+^CD24^−^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}E). In summary, these findings reveal a multi-lineage potential of the CD45^−^CD31^−^Sca1^+^CD24^+^ cell population that can give rise to a lineage of fate-committed adipogenic progenitor cells (APCs: CD45^−^CD31^−^Sca1^+^CD24^−^) that, in turn, give rise to a more mature pre-adipocyte (preAd: CD45^−^CD31^−^Sca1^−^Zfp423^+^) and that, in parallel, could yield a population of unilaterally committed osteochondrogenic progenitor cells (OPCs: CD45^−^CD31^−^Sca1^−^Pα^+^), under in vitro and vivo conditions ([Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}).

Osteo-Adipogenic Cell Populations Derive from a Mesenchymal, Non-endothelial, Non-hematopoietic Lineage {#sec2.2}
-------------------------------------------------------------------------------------------------------

To determine the developmental lineages of these four cell populations, lineage tracing was performed using mouse strains expressing Cre-recombinase under the control of promoters to mark hematopoietic (*Vav1*), endothelial (*Cdh5* and *Tek/Tie2*), or mesenchymal (*Prx1* and *Pα)* cells, or mature adipocytes (*Adipoq*) that were crossed to the mTmG-reporter mouse strain ([@bib2], [@bib23]). IF and flow cytometric analysis revealed a non-hematopoietic, non-endothelial, but mesenchymal lineage for the bone marrow-resident cells with purely adipogenic (APCs, adipocytes) or osteogenic (bone lining, osteocytes) potentials, which was also true for the CD45^−^CD31^−^Sca1^+^CD24^+^ stem cell-like population with tri-lineage potential ([Figures 2](#fig2){ref-type="fig"}A--2C).Figure 2Lineage Tracing of MAT Reveals a Mesenchymal, Non-endothelial, Non-hematopoietic Lineage(A) Representative merged IF images of bone-resident adipocytes from the indicated Cre-mTmG reporter mouse strains (green, EGFP; red, Perilipin; blue, DAPI).(B) Reporter analysis of bone lining cells and cortical bone-resident osteocytes (blue arrows; green, GFP; red, tdTomato; blue, DAPI).(C) FACS analysis of tdTomato^+^ and GFP^+^ cells in the CD45^−^CD31^−^Sca1^+^ population (percentages represent average values).(D) Quantification of GFP^+^ bone-resident adipocytes, bone lining cells, and osteocytes by image quantification and flow cytometric analysis of bone stroma cells populations (n = 3--4 mice/genotype). Mean ± SEM. Scale bars, 10 μm.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

As shown in previous reports on adipose tissues, CD45^+^ hematopoietic cells were exclusively traced by *Vav1*-Cre, whereas CD31^+^ cells did not trace to the expected *Cdh5*-Cre endothelial origin but rather to the *Vav1*-Cre hematopoietic driver ([Figure 2](#fig2){ref-type="fig"}D) ([@bib2]). Unexpectedly, only ∼50% of marrow adipocytes and CD45^−^CD31^−^Sca1^+^ APCs were marked by the *Pα*-Cre driver ([Figure 2](#fig2){ref-type="fig"}), contradicting our data from the *Pα-*EGFP reporter and also from the FACS analyses ([Figure S3](#mmc1){ref-type="supplementary-material"}F), but consistent with previous reports of incomplete recombination by this Cre strain ([@bib23], [@bib52]). Lastly, comparing the developmental lineages of adipogenic progenitors in *Prx1*-Cre:mTmG mice revealed labeling of inguinal WAT (iWAT) and skeletal muscle-resident CD45^−^CD31^−^Sca1^+^ cells that were comparable to bone, while brown adipose tissue (BAT) and epididymal WAT (eWAT) progenitors displayed almost no labeling ([Figure S3](#mmc1){ref-type="supplementary-material"}G). Moreover, gene expression patterns of in-vitro-differentiated progenitors from bone resembled most closely those derived from iWAT, with similar adipogenic differentiation capacity and expression of general adipogenic genes Peroxisome proliferator-activated receptor-*γ* (*Pparg*) and CCAAT/enhancer-binding protein-α (*Cebpa*) and absent or low expression of BAT markers Uncoupling protein-1 (*Ucp1*) and Cell Death-Inducing DFFA-Like Effector A (*Cidea*) ([Figures S3](#mmc1){ref-type="supplementary-material"}H--S3M), altogether indicating that the marrow adipocytic lineage is more closely related to white rather than brown adipocytes.

The Adipocytic Lineage Responds to Diet and Aging {#sec2.3}
-------------------------------------------------

We next examined gene expression in femora and tibiae from young (2 months) and old (25 months) mice. Consistent with previous reports ([@bib8]), expression of adipogenic marker *Pparg* was increased in old bones. However, adipogenic potential of CD45^−^CD31^−^Sca1^+^ progenitors isolated from old bones was unchanged. Conversely, osteogenic marker Osterix (Osx/*Sp7*) expression was significantly reduced, as was osteogenic capacity of CD45^−^CD31^−^Sca1^−^ progenitors ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C). Next, mice of both ages were fed a high-fat diet for either 24 hr (1dHFD) or 10 days (10dHFD). Accumulation of MAT was more pronounced in old animals after 10dHFD, while loss of trabecular bone was observed in aged animals independent of diet ([Figure 3](#fig3){ref-type="fig"}A). FACS analysis of young bones revealed a significant induction of CD45^−^CD31^−^Sca1^+^CD24^+^ and APC frequencies after 1dHFD that were no longer apparent in 10dHFD mice, suggesting that the rapid induction of adipocytic progenitor proliferation is a mechanism of short-term adaptation to diet ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}D). In mice aged 25 months, the same 1dHFD stimulus significantly increased the multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ and APC populations by ∼3- and 2-fold, respectively ([Figure 3](#fig3){ref-type="fig"}B).Figure 3Aging and High-Fat Diet Stimulate Expansion of the Adipocytic Lineage(A) H&E stains of femora from male mice aged 2 (young) or 25 months (old) maintained on standard diet (SD) or high-fat diet (HFD) for 24 hr (1dHFD) or 10 days (10dHFD).(B) Relative quantifications of CD31^−^CD45^−^Sca1^+^CD24^+^, APC, and OPC populations in young and 25-month-old mice on SD (white bars) compared to 1dHFD (gray bars, applies to all panels) (n = 9).(C) BrdU incorporation into CD31^−^CD45^−^Sca1^+^CD24^+^ and APCs from young and 15-month-old mice on SD or 1dHFD (n = 7--9).(D) Quantification of GFP^+^ cells in 2-month- and 15-month-old male *Zfp423*-EGFP reporter mice on SD or 1dHFD (n = 6). Graphs show cumulative data from at least two independent experiments. Mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ^∗∗∗∗^p \< 0.0001. Scale bar, 100 μm.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

BrdU incorporation was tested in young and 15-month-old *Zfp423*-EGFP mice, and it was significantly induced in multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ cells and APCs, an effect that was more pronounced in APCs from old mice ([Figure 3](#fig3){ref-type="fig"}C). Conversely, the OPC population was not affected by 1dHFD ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}E) and even showed a reduction in frequency and proliferation rates upon 10dHFD, an effect that was restricted to young animals ([Figures S4](#mmc1){ref-type="supplementary-material"}D and S4F). In a cohort of aged, 15-month-old *Zfp423*-EGFP mice, cell frequencies of the Zfp423^+^ preAds were significantly enhanced after 1dHFD, an effect that was significantly less pronounced in young animals ([Figure 3](#fig3){ref-type="fig"}D). Taken together, these findings on the bone-resident progenitor lineages could explain the enhanced accumulation of MAT observed during aging and in response to dietary cues.

Distinct Effects of Multipotent Cells and Committed Adipogenic Cells on Hematopoietic Reconstitution {#sec2.4}
----------------------------------------------------------------------------------------------------

Previous work has suggested a negative effect of MAT on hematopoiesis ([@bib38]). To test this more directly, competitive repopulation assays after a dose of lethal irradiation ([@bib28]) were performed after intratibial transplantation of the four cell populations ([Figure 4](#fig4){ref-type="fig"}A). As expected after irradiation ([@bib41]), increased amounts of adipocytes were observed in all groups after 5 weeks, an effect that was more pronounced after transplantation of fate-committed APCs and Zfp423^+^ preAds ([Figure 4](#fig4){ref-type="fig"}B). In full support of the sternal transplantation data, donor-derived (tdTomato^+^) adipocytes were only observed when multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ cells, APCs, or preAds, but not OPCs, were transplanted ([Figure 4](#fig4){ref-type="fig"}C). FACS analysis of bone marrows showed that donor-derived progenitors were retained 5 weeks after irradiation/transplantation, indicating long-term survival ([Figure 4](#fig4){ref-type="fig"}D, upper panels). Expression of *Zfp423*-driven EGFP was readily detectable in all marrows except after OPC transplants. All cells from the Zfp423^+^ preAd transplants maintained GFP expression, indicating no reversion ability toward GFP^−^ stages, whereas transplants of CD45^−^CD31^−^Sca1^+^CD24^+^ and APCs were only partially GFP^+^, indicating that these cells maintained their original identity but also gave rise to maturing Zfp423^+^ preAds ([Figure 4](#fig4){ref-type="fig"}D, middle panels). Consistent with our initial characterization, Zfp423^+^ cells no longer expressed Sca1 or CD24 ([Figure 4](#fig4){ref-type="fig"}D, lower panels).Figure 4Distinct Roles of Progenitor Populations during Hematopoietic Recovery(A) Schematic depiction of competitive hematopoietic repopulation assay.(B and C) H&E stains of injected tibiae (B), and tdTomato (red) and Perilipin (green) (C) IF co-localization on adipocytes in injected tibiae (green arrow, host derived; orange arrow, donor derived). Scale bars, 50 μm.(D) Fate analyses of transplanted cells. CD45^−^CD31^−^tdTomato^+^ cells (red squares, top row) were gated for expression of GFP (green squares, *Zfp423*-EGFP reporter; middle row). Zfp423^+^ cells were then assessed for expression of surface markers Sca1 and CD24 (bottom row).(E--G) Bone marrow cellularity (E), marrow chimerism (F), and donor-derived (G) LSK cells in injected and contralateral tibiae 5 weeks after irradiation.(H and I) Donor-derived LT-LSK (H) and donor-derived ST-LSK (I) hematopoietic stem cells in injected tibiae. Mean ± SEM (n = 7); p \< 0.05: a, versus no cells; b, versus OPC; c, versus CD31^−^CD45^−^Sca1^+^CD24^+^; d, versus APC; and e, versus preAd.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Tibiae that had received adipogenic transplants (APCs or preAds) 5 weeks prior to analysis showed significant reductions in cellularity but no change in overall bone marrow chimerism ([Figures 4](#fig4){ref-type="fig"}E and 4F). No differences in any of these parameters were observed in contralateral tibiae and regarding donor-derived myeloid and lymphoid cells, blood chimerism, or splenic hematopoietic progenitor cells, as these latter cells may also originate from other, non-injected bone sites ([Figures 4](#fig4){ref-type="fig"}E, 4F, and [S5](#mmc1){ref-type="supplementary-material"}A--S5D). Importantly, frequencies of hematopoietic lineage (Lin)^−^Sca1^+^c-Kit^+^ hematopoietic progenitor cells (LSK cells) and repopulation with donor-derived (CD45.1^+^) CD34^−^ long-term (LT)-LSK and CD34^+^ short-term (ST)-LSK cells were significantly reduced after adipogenic transplants ([Figures 4](#fig4){ref-type="fig"}G--4I). A similar trend of impaired hematopoietic reconstitution was observed after transplantation of APCs in a separate long-term reconstitution experiment 16 weeks after irradiation, but it did not reach statistical significance ([Figures S5](#mmc1){ref-type="supplementary-material"}E--S5G). Over the course of long-term reconstitution, no differences in blood chimerism or blood lymphoid or blood myeloid cells were observed in animals transplanted with APCs ([Figures S5](#mmc1){ref-type="supplementary-material"}H--S5J). FACS analysis revealed that transplanted cells were retained, and it confirmed that only CD45^−^CD31^−^Sca1^+^CD24^+^ and APCs gave rise to Zfp423^+^ preAds, albeit at markedly lower frequencies ([Figure S5](#mmc1){ref-type="supplementary-material"}K).

In contrast to adipogenic cells, transplantation of the multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ population led to significantly increased repopulation with donor-derived LT-LSKs and ST-LSKs in tibiae at 5 and 16 weeks after irradiation, while overall bone marrow cellularity remained unchanged ([Figures 4](#fig4){ref-type="fig"}E--4I and [S5](#mmc1){ref-type="supplementary-material"}E--S5G). Consistent with a potential involvement of this population in hematopoietic recovery, its relative frequency was transiently elevated after irradiation ([Figure S5](#mmc1){ref-type="supplementary-material"}L). Taken together, these analyses further establish the developmental hierarchy among the four cell populations, and they reveal the potential of the CD45^−^CD31^−^Sca1^+^CD24^+^ multipotent cells to give rise to the adipocytic lineage under pro-adipogenic stimuli and at the same time produce signals that support hematopoietic regeneration, whereas adipogenic cells significantly attenuate reconstitution.

The Adipocytic Lineage Inhibits Bone Regeneration {#sec2.5}
-------------------------------------------------

To determine the pathophysiological role of the adipocytic lineage during bone healing, all four populations isolated from rep^tdTom^ mice were transplanted into the vicinity of a stabilized tibia fracture and analyzed after 14 days ([Figures 5](#fig5){ref-type="fig"}A, upper panels, [S6](#mmc1){ref-type="supplementary-material"}A, and S6B). The μCT quantification showed a significant decrease of total bone mineral density (BMD) at the fracture site following transplantation of adipogenic populations when compared to the no-cell control group ([Figures 5](#fig5){ref-type="fig"}A, middle panels, and [5](#fig5){ref-type="fig"}B). Histomorphometric analysis of fracture/callus sites indicated reduced areas of mineralized tissue and increased amounts of cartilaginous tissues following transplantation of the adipogenic populations, e.g., APCs and preAds, compared to all other groups ([Figures 5](#fig5){ref-type="fig"}A, lower panels, and [5](#fig5){ref-type="fig"}C--5E). Due to the lineage restrictions shown in the cell culture and sternal transplants, these observations likely indicate delayed healing and, thus, that the cartilaginous structures are entirely derived from the host in the adipogenic transplant groups. Aside from adopting an adipogenic fate after intratibial injection ([Figure S3](#mmc1){ref-type="supplementary-material"}D), multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ and the two adipogenic populations produced some fibrous tissue, whereas only multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ and OPCs contributed to chondrogenic and osteogenic structures ([Figures S6](#mmc1){ref-type="supplementary-material"}C--S6G). These observations indicate a negative regulatory role of adipocytic cells during fracture healing, further establishing the detrimental role of MAT in aged bone homeostasis.Figure 5The Adipocytic Lineage Inhibits Bone Healing(A) Red fluorescence in tibiae (top panels), μCT images (middle panels), and representative Movat-Pentachrome stains (lower panels; yellow, mineralized bone; red, new bone; blue, cartilage; purple, nuclei) of fracture calluses 14 days after fracture and intratibial injection of the indicated cell populations.(B) Total bone mineral density (BMD) by μCT (n = 6).(C--E) Histomorphometry of mineralized bone volume (BV) and non-mineralized callus (C) as fibrous tissue (FV) (D), and cartilage tissue (CV) volumes (E), all normalized to total callus volume (TV) (n = 8). Mean ± SEM; p \< 0.05: a, versus no cells; b, versus OPC; and c, versus CD31^−^CD45^−^Sca1^+^CD24^+^. Scale bar, 100 μm.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

DPP4 Released from MAT Inhibits Bone Healing {#sec2.6}
--------------------------------------------

To identify potential negative regulators of regeneration processes, RNA sequencing (RNA-seq) was used to further characterize the molecular identity of all four populations ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B). Principal-component and hierarchical clustering analyses clearly supported the distinct nature of each population, providing a second line of evidence for the lineage restriction of adipogenic commitment of the closely related APC and preAd populations ([Figures 6](#fig6){ref-type="fig"}A--6C). Differential expression (DE) analysis produced several sets of known and potential new candidate genes to define each population ([Figures 6](#fig6){ref-type="fig"}D--6G; [Table S5](#mmc2){ref-type="supplementary-material"}). For instance, canonical stem cell markers (e.g., *Nog*, *Il1rn*, and *Myc*) were enriched in the CD45^−^CD31^−^Sca1^+^CD24^+^ multipotent stem cell population ([Figure 6](#fig6){ref-type="fig"}D). Moreover, signals known to regulate hematopoietic stem cell (HSC) quiescence and maintenance (e.g., *Cxcl12*, *Kitl*/*Scf*, and *Vcam*-*1*), showed the highest expression in this population, along with the highest, but not exclusive, expression level of LepR that was also expressed in the other cells types. The OPC population expressed the classical osteogenic (e.g., *AlpI*, *Dmp1*, and *Col1α1*/*2*) and chondrogenic markers (e.g., *Acan*, *Col2α1*, and *Sox9*), as well as previously described skeletal stem cell markers (*Itga5* and *CD200*), at elevated levels ([Figure 6](#fig6){ref-type="fig"}E; [Table S5](#mmc2){ref-type="supplementary-material"}) ([@bib7]). The adipogenic populations expressed high levels of markers that have been linked to the adipocytic lineage (i.e., *Cd34*, *Ebf2*, and *Dpp4*) ([@bib1], [@bib40], [@bib49]) or adipocyte differentiation (i.e., *Vim*, *Ppara*; [Figures 6](#fig6){ref-type="fig"}F and 6G) ([@bib13], [@bib16]). As expected, expression of *Zfp423* was highest in Zfp423^+^ preAds ([Figure 6](#fig6){ref-type="fig"}F). Thus, our RNA-seq analysis confirmed the cellular characteristics of the four populations, and it establishes the CD45^−^CD31^−^Sca1^+^CD24^+^ multipotent stem cell population as a population expressing elevated levels of *Cxcl12* and *Lepr* that are important regulators of HSCs and osteogenesis ([@bib17], [@bib51]).Figure 6RNA-Seq Defines the Cellular Identities of Bone-Resident Sub-populations(A--C) The principal-component analysis (PCA; A), correlations scores (B) of the top ten genes driving PC1 and PC2 in (A), and hierarchical clustering analyses (C) of RNA-seq from all four cell populations.(D--G) Heatmaps of selected differentially expressed (DE) genes, divided by candidates reported in the literature (known, asterisks indicate no significant DE between individual groups) and novel markers, enriched in CD31^−^CD45^−^Sca1^+^CD24^+^ (D), OPC (E), APCs and preAds combined (F), and APC or preAd (G) cell populations.See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S5](#mmc2){ref-type="supplementary-material"}.

To identify signals that could mediate the negative effects of adipogenic cells on bone healing, we screened the dataset for secreted factors that were significantly enriched in the adipogenic populations. Among the most significantly regulated secreted factors was the gene encoding for Dipeptidyl peptidase-4 (*Dpp4*), a protease shed from the plasma membrane that is an important target of clinical diabetes treatments ([Figure 7](#fig7){ref-type="fig"}A) ([@bib1], [@bib29]). Consistent with the RNA-seq data, CD26 (the membrane-bound form of DPP4) was enriched on the surface of adipogenic cell populations, and only CD45^−^CD31^−^Sca1^+^CD24^+^ and APCs, but not OPCs, released DPP4 into the medium after adipogenic differentiation ([Figures S7](#mmc1){ref-type="supplementary-material"}C and S7D). Expression of *Dpp4* was increased in distal tibiae of old mice that contain most ectopic adipocytes, and explant cultures of old tibiae released greater amounts of DPP4 ([Figures 7](#fig7){ref-type="fig"}B and 7C). While treatment of CD45^−^CD31^−^Sca1^+^CD24^+^ and APCs with the DPP4 inhibitor sitagliptin had no effect on adipogenesis, it significantly enhanced osteogenic gene expression and mineralization of multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ and OPCs during osteogenic differentiation ([Figures 7](#fig7){ref-type="fig"}D, 7E, [S7](#mmc1){ref-type="supplementary-material"}E, and S7F). While no positive effect was found in untreated OPC transplants ([Figure 5](#fig5){ref-type="fig"}), the improved OPC function following sitagliptin may serve to promote bone healing. Exposure to recombinant DPP4 slightly impaired osteogenic, but did not alter adipogenic differentiation ([Figures S7](#mmc1){ref-type="supplementary-material"}G--S7J). Treatment of mice with two DPP4 inhibitors, Diprotin A and sitagliptin, significantly accelerated tibia fracture healing ([Figures S7](#mmc1){ref-type="supplementary-material"}K and S7L), and intraperitoneal (i.p.) injections of sitagliptin for 9 days significantly increased the frequency of osteogenic progenitors while decreasing the frequency of APCs in non-fractured tibiae ([Figure 7](#fig7){ref-type="fig"}F). Administration of sitagliptin was sufficient to abolish the negative effects of transplanted adipogenic cells on bone healing while surprisingly promoting bone healing after OPC transplants ([Figures 7](#fig7){ref-type="fig"}G--7I). Lastly, transplantation of *Dpp4*-deficient APCs similarly prevented the inhibitory effects of APCs on fracture healing ([Figures 7](#fig7){ref-type="fig"}J--7L).Figure 7DPP4 Inhibition Reverses the Negative Effects of Adipogenic Cells on Bone Regeneration(A) Gene expression intensities of *Dpp4* from RNA-seq analysis.(B) *Dpp4*-mRNA levels in whole proximal and distal tibiae of young (2 months) and old (15 months) male mice (n = 5).(C) DPP4 secretion by whole tibia explants from young and old mice (n = 4).(D and E) The mRNA levels (D) of *Runx2* and *Osterix* (Osx/*Sp7*) and Alizarin Red S staining and quantification (E) of CD45^−^CD31^−^Sca1^+^CD24^+^ and OPCs either treated with PBS (control, white bars) or sitagliptin (100 μM, black bars) during osteogenic differentiation (n = 3). Scale bars, 30 μm.(F) FACS analysis of OPC, CD45^−^CD31^−^Sca1^+^CD24^+^, and APC cell frequencies in tibiae from male mice either i.p. injected with PBS (white bars) or sitagliptin for 9 days (black bars; n = 9--10). Mean ± SEM; ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗∗^p \< 0.0001.(G--I) Representative Movat-Pentachrome stains (G) of fracture calluses from control PBS-treated mice that received osteogenic (PBS/OPC) or adipogenic (PBS/APC) intratibial transplants and animals treated with sitagliptin for 1 week after fracture and receiving the same transplants of osteogenic (Sita/OPC) or adipogenic (Sita/APC) cells. Fracture callus total volumes (TVs) were analyzed for mineralized callus volume (H, BV/TV) and fibrous tissue volumes (I, FV/TV) (n = 5--7).(J--L) Representative Movat-Pentachrome stains and histomorphometric analyses (as in G--I) of fracture calluses 14 days after injury from mice that received osteogenic (OPC) or adipogenic (APC) intratibial transplants from either DPP4-KO or wild-type (WT) animals (n = 9). Mean ± SEM; p \< 0.05: a, versus PBS or WT/OPC; b, versus PBS or WT/APC; c, versus sitagliptin or DPP4-KO/OPC; and d, versus sitagliptin or DPP4-KO/APC. Scale bars, 100 μm.See also [Figure S7](#mmc1){ref-type="supplementary-material"} and [Table S6](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Marrow adipogenesis is a highly regulated process that responds to a variety of endocrine signals, dietary cues, and pathologies ([@bib41]), reflecting the necessity of a highly adaptive reservoir of stem/progenitor cells. Our study establishes a unidirectional developmental hierarchy of the bone marrow adipocytic lineage from a multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ stem cell-like population toward distinct progenitor cell populations with unilaterally committed osteochondrogenic or adipogenic fates. Our results further suggest that adipogenic progenitors irreversibly mature toward a preAd stage: while APCs can maintain their identity they also give rise to Zfp423^+^ preAds that cannot revert to Sca1^+^Zfp423^−^ progenitors. This unidirectional process enables the definition of two distinct maturation stages that subsequently differentiate into mature Zfp423^+^ marrow adipocytes. These findings are consistent with recent studies that have defined the heterogeneity of mesenchymal cell populations in WAT and BAT in some detail ([@bib2], [@bib18], [@bib40], [@bib43]). The adipocytic as well as osteochondrogenic populations of the bone derive from a mesenchymal and non-hematopoietic, non-endothelial lineage. Previous work has also shown that neural crest-derived, Nestin^+^ cells are the likely developmental origin of the adult mesenchymal cells described here ([@bib19], [@bib35], [@bib37], [@bib47]).

Our data on developmental lineages, differentiation capacity, and adipocyte phenotype suggest that marrow-resident adipocyte progenitors more closely resemble white, rather than brown, adipogenic cells. This is consistent with previous reports, but it does not rule out specific differences in endocrine function between WAT and MAT ([@bib41]). However, our RNA-seq analysis shows that several genes enriched in bone-resident preAds are also expressed in committed brown pre-adipocytes (e.g., *Ebf2*, *Entpd2*, *Fam129a*, and Acy3) ([@bib49]), which would support at least some potential similarities to the BAT lineage ([@bib22]).

A high-fat diet rapidly increases expansion of the adipogenic, but not the osteochondrogenic lineage. This induction is more pronounced in aged bone marrow. Whether aging also affects expansive capacities of subsets of adipose tissue-resident progenitors remains to be determined, but our data clearly suggest that this process may be involved in the pathogenic processes related to MAT accumulation. This observation is supported by a report on leptin-mediated regulation of diet-induced adipogenesis in the bone marrow ([@bib51]). Of note, decreased numbers of OPCs after high-fat diet feeding were only observed in young animals, which could be due to leptin resistance as observed in aged animals ([@bib15]) but which would also suggest that expansion of adipogenic cells may not be exclusively leptin dependent.

Sca1^+^ cells, e.g., the multipotent CD45^−^CD31^−^Sca1^+^CD24^+^ population, as well as APCs, associate to L type vessels that are known to host HSCs ([@bib45]) and occur in the vicinity of the endosteum and could, thereby, readily affect the hematopoietic niches or contribute to osteogenic processes. Interestingly, a multipotent differentiation potential of at least partially overlapping populations of bone-resident populations, such as PαS (Sca1^+^Pα^+^) cells, cells expressing LepR, or Nestin-expressing stromal cells, has been described before ([@bib31], [@bib34], [@bib51], [@bib52]), but these populations overlap at least partially with several of the populations described here. For instance, almost all LepR^+^ cells are Pα^+^ and contain all CD45^−^CD31^−^Sca1^+^ cells ([@bib52]). Our clonal analysis of CD45^−^CD31^−^Sca1^+^CD24^+^ cells identified this population as a highly homogeneous pool of multipotent cells, indicating additional enrichment in this stem cell-like sub-population. In support of this observation, clonal analysis of PαS or LepR^+^ cells showed multipotency only in a smaller subset of clones that may have derived from sub-populations expressing CD24 ([@bib34], [@bib52]). Importantly, the multipotent stem cell-like population also promotes hematopoietic repopulation and is enriched for cells expressing the hematopoiesis maintenance cytokine CXCL12 ([@bib17], [@bib52]). In comparison to the other three cell types defined in our study, we find that CD45^−^CD31^−^Sca1^+^CD24^+^ multipotent cells also express the highest levels of *Lepr* and other pro-hematopoietic signals, such as *Kitl/Scf* and *Vcam1*, and, thus, could represent a further purification step of a mesenchymal stem cell that supports hematopoiesis ([@bib9], [@bib27]). In summary, while we cannot exclude that several independent adipogenic and osteogenic lineages exist in bone, our study strongly suggests that the CD45^−^CD31^−^Sca1^+^CD24^+^ cell type, the skeletal equivalent of previously described adipocyte stem cells in WAT ([@bib40]), can give rise to populations unilaterally committed to either lineage and provides maintenance signals essential for the hematopoietic niche.

Consistent with previous reports ([@bib7], [@bib46]), we describe a committed OPC population that may at least partially arise from the CD45^−^CD31^−^Sca1^+^CD24^+^ multipotent stem cells. Comparison of expression signatures suggests these correspond to previously described skeletal stem cells ([@bib7]), which have been proposed to be one of two distinct skeletogenic stem cell populations contributing to post-natal development of bone ([@bib50]). In our study, *Grem1* mRNA was detected in all populations but was highest in the multipotent cells. While [@bib50] clearly showed that Grem1^+^ cells are mostly CD45^−^CD31^−^Sca1^−^ skeletal stem cells, a small subset of Grem1^+^ cells was also Sca1^+^ and could thus also mark the multipotent stem cell-like population we describe here. Further work is required to determine the extent to which CD45^−^CD31^−^Sca1^+^CD24^+^ cells contribute to the osteogenic lineages in embryonic and adult stages.

Ectopic adipocyte accumulation in the bone marrow cavity is believed to contribute to age-related impairment of bone regeneration and hematopoiesis ([@bib5], [@bib12], [@bib26], [@bib38], [@bib44]). An increased risk for fractures and complications, such as non-unions, is associated with aging- and obesity-induced MAT accumulation ([@bib39]). Bone healing is tightly regulated with an initial inflammatory phase, followed by cartilaginous callus formation, the deposition of a fibrous matrix, and subsequent mineralization through osteogenic cells ([@bib11]). We here identify the cellular basis for the pro-adipogenic shift observed during high-fat diet feeding and aging. Cells committed to the adipogenic lineage not only inhibited bone healing but also acute hematopoietic reconstitution. The limited negative effect of the adipocytic lineage during long-term hematopoietic recovery further suggests that the lack of a pro-adipogenic stimulus is beneficial to bone homeostasis. Follow-up studies will have to determine whether these effects are also true for distinct processes, such as bone remodeling as opposed to bone healing, and subtypes of healthy and pathological MAT ([@bib6], [@bib42]) and whether sex-specific differences occur as only male mice were analyzed in this study. A potential mediator of such detrimental effects on bone homeostasis is DPP4, as it was recently shown to impair hematopoietic recovery and bone health ([@bib4], [@bib21], [@bib33]). Our results provide mechanistic insights into the beneficial effects of DPP4 inhibitors during bone regeneration by targeting the adipocytic lineage, and they potentially link MAT as a source of DPP4 to the pathophysiology of systemic insulin resistance. In summary, we here delineate the ontology of MAT and the adipocytic lineage, which exerts negative effects on bone healing and hematopoiesis. These findings suggest that MAT accumulation causes the age-related dysfunction of the bone marrow niches and can be implicated in multiple pathological processes that interfere with appropriate maintenance of bone tissue repair and the hematopoietic system.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-Mouse Ly-6A/E (Sca-1) APC (Clone: D7)eBioscienceCat\#: 17-5981Anti-Mouse Ly-6A/E (Sca-1) Alexa Fluor 700 (Clone: D7)eBioscienceCat\#: 56-5981Anti-Mouse Ly-6A/E (Sca-1) APC/Cy7 (Clone: D7)BiolegendCat\#: 108125Anti-Mouse CD45 FITC (Clone: 30-F11)eBioscienceCat\#: 11-0451Anti-Mouse CD45 APC (Clone: 30-F11)BiolegendCat\#: 103111Anti-Mouse CD45 PE (Clone: 30-F11)BioscienceCat\#: 12-0451Anti-Mouse CD31 (PECAM-1) FITC (Clone: 390)eBioscienceCat\#: 11-0311Anti-Mouse CD31 (PECAM-1) APC (Clone: 390)eBioscienceCat\#: 17-0311Anti-Mouse CD31 (PECAM-1) PE-Cyanine7 (Clone: 390)eBioscienceCat\#: 25-0311Anti-Mouse CD140a (PDGF Receptor a) APC (Clone: APA5)BiolegendCat\#: 135907Anti-Mouse CD140a (PDGF Receptor a) PE (Clone: APA5)eBioscienceCat\#: 12-1401Anti-Mouse CD24 APC-eFluor 780 (Clone: M1/69)eBioscienceCat\#: 47-0242Anti-Mouse CD24 PE (Clone: 30-F1)eBioscienceCat\#: 12-0241Anti-Mouse CD26 PerCP-Cyanine5.5 (Clone: H194-112)eBioscienceCat\#: 45-0261Anti-Mouse CD45.1 PE (Clone: A20)eBioscienceCat\#: 12-0453Anti-Mouse CD45.1 APC (Clone: A20)eBioscienceCat\#: 17-0453Anti-Mouse CD45.2 Alexa Fluor 700 (Clone: 104)eBioscienceCat\#: 56-0454Anti-Mouse CD11b PE (Clone: M1/70)eBioscienceCat\#: 12-0112Anti-Mouse Ly-6G (Gr-1) PE (Clone: RB6-8C5)eBioscienceCat\#: 12-5931Anti-Mouse CD19 APC-eFluor 780 (Clone: eBio1D3)eBioscienceCat\#: 47-0193Anti-Mouse CD3e APC-eFluor 780 (Clone: 145-2C11)eBioscienceCat\#: 47-0031Mouse Hematopoietic Lineage FITC Cocktail (Clone: 17A2, RA3-6B2, M1/70, TER-119, RB6-8C5)eBioscienceCat\#: 22-7770Anti-Mouse CD117 (c-Kit) APC (Clone: 2B8)eBioscienceCat\#: 17-1171Anti-Mouse CD34 Alexa Fluor 700 (Clone: RAM34)eBioscienceCat\#: 56-0341Anti-Mouse CD16/CD32 PE-Cyanine7 (Clone: 93)eBioscienceCat\#: 25-0161Rabbit anti-RFP (tdTomato)AbcamCat\#: ab62341Goat anti-GFPNovusBiologicalsCat\#: NB100-1770Rat anti-CD45NovusBiologicalsCat\#: NB100-77417Goat anti-PerilipinAbcamCat\#: ab61682Rabbit anti-PerilipinSigmaCat\#: P1873Rat anti-CD31DianovaCat\#: DIA-310Rat anti-Sca1AbcamCat\#: ab25195Rat anti-BrdUCedarlaneCat\#: CL2700APMouse anti-AggrecanMerck MilliporeCat\#: MABT84Goat anti-OsteocalcinBioRadCat\#: 7060-1815Goat anti-CD24AbcamCat\#: ab202963Alexa Fluor 488 goat anti-rabbitAbcamCat\#: ab150077Alexa Fluor 488 chicken anti-goatLife TechnologiesCat\#: A-21467Alexa Fluor 488 donkey anti-ratLife TechnologiesCat\#: A-21208Alexa Fluor 488 goat anti-mouseAbcamCat\#: ab150113Alexa Fluor 568 goat anti-rabbitAbcamCat\#: ab175471Alexa Fluor 594 donkey anti-rabbitLife TechnologiesCat\#: A-21207Alexa Fluor 594 donkey anti-goatAbcamCat\#: ab150132Alexa Fluor 680 donkey anti-rabbitThermoFisherCat\#: A10043Anti-β-Actin Peroxidase-conjugatedSigmaCat\#: A3854Anti-human/mouse UCP1R&D SystemsCat\#: MAB6158Peroxidase goat anti-mouseAbcamCat\#: ab97023**Chemicals, Peptides, and Recombinant Proteins**CalceineBioscienceCat\#: 65-0855-39Propidium Iodide (PI)SigmaCat\#: P4170Recombinant Mouse DPPIV/CD26 ProteinR&D SystemsCat\#: 954-SEDiprotin A (Ile-Pro-Ile)SigmaCat\#: I9759SitagliptinbiomolCat\#: Cay-13252-250Cal-Rite FixativeThermoFisherCat\#: 10599428Roti-Histofix 4%Carl RothCat\#: P087.3Sudan Black BSigmaCat\#: 199664Fluoromount-GeBioscienceCat\#: 00-4958-02Oil Red OSigmaCat\#: O0625Alizarin Red SCarl RothCat\#: A5533-25GAlcian Blue 8GXSigmaCat\#: A3157Crystal VioletSigmaCat\#: C0775BrdUSigmaCat\#: B5002D-Luciferin - K+ Salt Bioluminescent SubstratePerkin ElmerCat\#: 122796MCDB201 MediaSigmaCat\#: M6770DexamethasoneSigmaCat\#: D-4902L-Ascorbic acid 2-phosphateSigmaCat\#: A8960Insulin-transferrin-selenium (ITS) mixSigmaCat\#: I3146Linoleic acid-AlbuminSigmaCat\#: L9530Epidermal growth factorPeproTechCat\#: 315-09Leukemia inhibitory factorMerckMilliporeCat\#: ESG1107Platelet-derived growth factor BBPeproTechCat\#: 315-18Basic fibroblast growth factorSigmaCat\#: F0291IndomethacinSigmaCat\#: I7378Recombinant Human InsulinRocheCat\#: 11376497001IsobutylmethylxanthineSigmaCat\#: I58793,3′,5-triiodo-L-thyronine (T3)SigmaCat\#: T6397β-glycerophosphateSigmaCat\#: G9891L-thyroxineSigmaCat\#: T0397Transforming growth factor β1PeproTechCat\#: 100-21**Critical Commercial Assays**DPP4 ELISAThermoFisherCat\#: EMDPP4RNeasy Plus Micro KitQIAGENCat\#: 74034SMARTer PCR cDNA Synthesis kitClontechCat\#: 634925Advantage 2 PCR kitClontechCat\#: 639207Bioanalyzer DNA High-Sensitivity kitAgilent TechnologiesCat\#: 5067Nextera XT DNA Sample Preparation KitIlluminaCat\#: FC-131Nextera Index KitIlluminaCat\#: FC-131**Deposited Data**RNA-seq DataEuropean Nucleotide Archive (ENA), <http://www.ebi.ac.uk/ena>ENA: ERP013883**Experimental Models: Organisms/Strains**Mouse: R6/2: C57BL/6JThe Jackson LaboratoryJAX: 000664Mouse: R6/2: B6(Cg)-Tyr^c-2J^/JThe Jackson LaboratoryJAX: 000058Mouse: R6/2: B6.Cg-Tg(Gt(ROSA)26Sor-EGFP)I1Able/JThe Jackson LaboratoryJAX: 007897Mouse: R6/2: B6.129S4-Pdgfra^tm11(EGFP)Sor^/JThe Jackson LaboratoryJAX: 007669Mouse: R6/2: B6;FVB-Tg(Zfp423-EGFP)7Brsp/JThe Jackson LaboratoryJAX: 019381Mouse: R6/2: B6.SJL-*Ptprc*^*a*^*Pepc*^*b*^/BoyJThe Jackson LaboratoryJAX: 002014Mouse: R6/2: B6.129(Cg)-*Gt(ROSA)26Sor*^*tm4(ACTB-tdTomato,-EGFP)Luo*^*/J*The Jackson LaboratoryJAX: 007676Mouse: R6/2: FVB.129S6(B6)-*Gt(ROSA)26Sor*^*tm1(Luc)Kael*^*/J*The Jackson LaboratoryJAX: 005125Mouse: R6/2: B6.Cg-Tg(Prrx1-cre)1Cjt/JThe Jackson LaboratoryJAX: 005584Mouse: R6/2: C57BL/6-Tg(Pdgfra-cre)1Clc/JThe Jackson LaboratoryJAX: 013148Mouse: R6/2: B6;FVB-Tg(Adipoq-cre)1Evdr/JThe Jackson LaboratoryJAX: 010803Mouse: R6/2: B6;129-Tg(Cdh5-cre)1Spe/JThe Jackson LaboratoryJAX: 017968Mouse: R6/2: B6.Cg-Tg(Vav1-icre)A2Kio/JThe Jackson LaboratoryJAX: 008610Mouse: R6/2: B6.Cg-Tg(Tek-cre)1Ywa/JThe Jackson LaboratoryJAX: 008863Mouse: Dpp4^tm1Nwa^[@bib29]MGI ID: [2150161](mgi:2150161){#intref0015}**Sequence-Based Reagents**qPCR Primer sets: please see [Table S6](#mmc1){ref-type="supplementary-material"}This paperN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents may be directed to and will be fulfilled by the Lead Contact, Tim J. Schulz (<tim.schulz@dife.de>). Animal strains used in this study are covered by MTAs prepared with the respective strain providers.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

All procedures were approved by the ethics committee for animal welfare of the State Office of Environment, Health, and Consumer Protection (State of Brandenburg, Germany). Animals were housed in a controlled environment (20 ± 2°C, 12/12 hr light/dark cycle), maintained on a SD (Ssniff, Soest, Germany), or fed a HFD (45% energy from fat, D12451, Research Diets, New Brunswick, NJ,USA) for 1 and 10 days. Male mice were used for all experiments at the indicated ages were applicable. All following mouse strains were obtained from The Jackson Laboratory: C57BL/6J, B6(Cg)-Tyr^c-2J^/J (B6-albino), B6.Cg-Tg(Gt(ROSA)26Sor-EGFP)I1Able/J, B6.129S4-Pdgfra^tm11(EGFP)Sor^/J (Pα-eGFP reporter), B6;FVB-Tg(Zfp423-EGFP)7Brsp/J (Zfp423-eGFP reporter), B6.SJL-*Ptprc*^*a*^ *Pepc*^*b*^/BoyJ (CD45.1), B6.129(Cg)-*Gt(ROSA)26Sor*^*tm4(ACTB-tdTomato,-EGFP)Luo*^*/J* (mTmG-reporter), FVB.129S6(B6)-*Gt(ROSA)26Sor*^*tm1(Luc)Kael*^*/J* (Rosa26-Luciferase reporter), B6.Cg-Tg(Prrx1-cre)1Cjt/J, C57BL/6-Tg(Pdgfra-cre)1Clc/J, B6;FVB-Tg(Adipoq-cre)1Evdr/J, B6;129-Tg(Cdh5-cre)1Spe/J, B6.Cg-Tg(Vav1-icre)A2Kio/J, B6.Cg-Tg(Tek-cre)1Ywa/J. The strain Dpp4^tm1Nwa^ ([@bib29]; DPP4-KO) was provided from a colony maintained by Dr. Hua Fan from Charité University of Medicine, Berlin, Germany. Mouse strains expressing Cre-recombinase under promoter control of the hematopoietic (Vav1), endothelial (Cdh5 and Tek/Tie2), mesenchymal (Prx1 and PDGFRα), or mature adipocyte (AdipoQ) lineage markers were intercrossed with the mTmG-reporter mouse strain that constitutively expresses the membrane-bound red fluorescent protein tdTomato (from a loxP-flanked cDNA). Cre-mediated recombination leads to excision of the tdTomato-cassette and activates expression of green fluorescent protein instead. For transplantation experiments, Zfp423-eGFP reporter mice were either intercrossed with mTmG-reporter mice (rep^tdTom^), or to AdipoQ-Cre mice and a lox-Stop-lox reporter strain expressing luciferase after Cre-mediated removal of the floxed Stop-cassette from the Rosa26-locus (rep^AdiLuc^). Freshly sorted primary murine cells were used throughout this study and isolated by FACS and cultured as described before ([@bib43], [@bib46]). Cells were therefore not authenticated. For cultivation, a complex medium of 60% DMEM low glucose (Invitrogen) and 40% MCDB201 (Sigma) was supplemented with 100 U/mL penicillin and 1,000 U/mL streptomycin (Invitrogen). 2% FBS, 1 × insulin-transferrin-selenium (ITS) mix, 1 × linoleic acid conjugated to BSA, 1 nM dexamethasone, and 0.1 mM L-ascorbic acid 2-phosphate (all from Sigma) were added. Before use, growth factors were added to the medium:10 ng/mL epidermal growth factor (PeproTech), 10 ng/mL leukemia inhibitory factor (MerckMillipore), 10 ng/mL platelet-derived growth factor BB (PeproTech), and 5 ng/mL basic fibroblast growth factor (bFGF; Sigma-Aldrich). The bFGF was added daily throughout the culture period except where stated otherwise. For adipogenic differentiation cells were induced for 48 hr after three days of expansion, followed by a differentiation period of 5 days. For adipogenic differentiation, induction medium (growth medium without growth factors) containing 5 μg/mL human insulin (Roche Applied Science), 50 μM indomethacin, 1 μM dexamethasone, 0.5 μM isobutylmethylxanthine, 1 nM 3,3′,5-triiodo-L-thyronine (T3) (all from Sigma-Aldrich) was added for 48 hr, followed by further differentiation in growth medium without growth factors and the addition of T3 and insulin only. Oil Red O staining was performed by fixing cells with 4% Histofix for 15 min at room temperature. For the preparation of Oil Red O working solution, a 0.5% stock solution in isopropanol was diluted with distilled water at a ratio of 3:2. The working solution was filtered and applied to fixed cells for at least one hour at room temperature. Cells were washed four times with tap water before evaluation. For quantification, Oil Red O was extracted by adding a defined volume of isopropanol and absorbance was read in a micro-plate reader (Synergy H1, BioTek) at 510 nm. To induce osteogenic differentiation, pre-confluent cells were supplemented with osteogenic medium (DMEM low glucose (Invitrogen)) with 10% FBS, 100 nM Dexamethasone, 0.2 mM L-ascorbic acid 2-phosphate, 10mM β-glycerophosphate, and 50 ng/mL L-thyroxine) for 14 days. Cells were then formalin-fixed and stained with 2% Alizarin Red S (Roth) in distilled water. Wells were washed twice with PBS and once with distilled water. De-staining was conducted to quantitatively determine mineralization by adding a 10% cetylpyridinium chloride solution. Absorbance was measured in a micro-plate reader (Synergy H1, BioTek) at 570 nm. A micromass culture was used for the chondrogenesis assay. To this end, a 5 μL droplet of cell suspension (appr. 1.5 × 10^7^ cells/mL) was pipetted in the center of a well (48-well plate). After cultivating the micromass culture for 2 hr in the incubator, warm chondrogenic media (DMEMhigh (Invitrogen)) with 10% FBS, 100 nM Dexamethasone, 1 μM L-ascorbic acid-2-phosphate, 10x ITS mix, and 10 ng/ml Transforming growth factor β1) was added. Cell media was changed every other day. After 21 days cells were fixed and stained with 1% Alcian-Blue staining (Sigma) for 30 min at room temperature. Cells were rinsed three times with 0.1 M HCl. To neutralize acidity a washing step with dH2O was conducted before microscopic analysis. For DPP4 in vitro experiments cell populations were differentiated with adipogenic or osteogenic assays as described above. Mouse recombinant DPP4 (250 ng/mL; R&D Systems) or DPP-4 inhibitor Sitagliptin (100 μM; biomol) were added to differentiation cocktails from day 3 (adipogenic induction) during adipogenesis or day 0 during osteogenesis until the end of differentiation experiments. DPP4 secretion into cell culture media was determined by ELISA (ThermoFisher). Either supernatant of freshly isolated tibia explants maintained in culture media for 24 hr or supernatant from cell populations following 10 days of adipogenic differentiation were used. CFU-F assay was conducted as follows: Freshly isolated cell populations were seeded in expansion media at 500 cells per 6-well plate. Medium was changed every other day. At day 10 cells were fixed and stained with Crystal Violet (Sigma). Colonies consisting of more than 20 cells were counted as CFU. At least 6 independent assays were performed per cell population. For total recovery rate experiments cell populations were seeded as described for the CFU-F assay. Analysis of fixed and Crystal Violet stained cell populations was conducted on day 7, 11, and 15 by quantification of total cell invasion area of well-plate surface using ImageJ software.

Method Details {#sec4.4}
--------------

### Flow cytometry & cell sorting {#sec4.4.1}

Flow cytometry and cell sorting were performed on a FACS Aria III cell sorter (BD Biosciences) and analyzed using FlowJo software (Tree Star). Soft-tissue free bones (tibia/femur) were crushed with bone scissors and incubated for 1 hr in a shaking water bath at 37°C in 10 mL of 20% FBS/PBS containing 0.5% type-2 collagenase (CellSystems). The suspension was filtered through a 70 μm mesh to remove bone fragments and centrifuged at 1200 rpm for 5 min at 4°C. The pellet was re-suspended in ACK (Ammonium-Chloride-Potassium) lysing buffer to eliminate red blood cells and centrifuged again at 1200 rpm for 5 min at 4°C. The pellet was re-suspended in 100 μL sorting buffer (2% FBS/PBS) and stained with antibodies for at least 30 min at 4°C. The applied FACS antibodies can be found in the [Key Resources Table](#sec4.1){ref-type="sec"}. Living cells were gated for lack of PI (propidium iodide; 1:1,000 diluted stock solution: 1 μg/mL in water) fluorescence and accumulation of Calcein (1:1,000 dilution; stock of 1 mg in 215 μL DMSO). Compensation, fluorescence-minus-one control based gating, and FACS-isolation was conducted as described before using the antibody combinations as indicated in the respective figures and legends ([@bib43]).

### Single-cell clonal assays {#sec4.4.2}

For the co-culture approach, a feeder layer of CD45^-^CD31^-^Pα^+^ cells was isolated from long bones of 8-weeks old male C57BL/6J mice and seeded in 100 μL of expansion medium at 750 cells per well of a 96-well plate. On the next day, a single CD45^-^CD31^-^Sca1^+^CD24^+^tdTomato^+^ cell freshly isolated from 8-weeks old male Rosa26-mTmG mice was FAC-sorted into each well. Cells were expanded for 10 days to sub-confluency with media changes every other day. After 10 days, clonal expansion of a single cell was verified by fluorescence microscopy. Wells containing a readily detectable single colony of tdTomato^+^ cells were trypsinized, washed, and collected in 100 μL sorting medium. Five to ten cells (per condition) of each clone were directly FAC-sorted onto freshly prepared 96-well plate feeder layers of expanded CD45^-^CD31^-^Pα^+^ cells for adipogenic and osteogenic differentiation protocols, or onto a micromass culture for chondrogenic differentiation. At the end of the differentiation assays clones were analyzed for their differentiation capacity by immunocytochemistry. A tdTomato positive clone was considered adipogenic if it co-stained with Perilipin, osteogenic if it co-stained with Osteocalcin, and chondrogenic if it co-stained with Aggrecan. Alternatively, in a feeder cell-free assay, a single CD45^-^CD31^-^Sca1^+^CD24^+^ cell, freshly isolated from 8-weeks old male C57BL/6J mice, was FAC-sorted into a well of a 96-well plate without feeder cells. Single cells were expanded for 10 days with media changes every other day. After 10 days, clones giving rise to colonies were re-seeded in a new 96-well plate and expanded until sub-confluency. Clones were then used for tri-differentiation assays. At the end of differentiation Oil Red O staining was conducted for adipogenesis and immunocytochemistry for osteogenesis (Osteocalcin) and chondrogenesis (Aggrecan). Images were acquired with a Keyence BZ-9000 (Biorevo) fluorescence microscope.

### Histology {#sec4.4.3}

Isolated bones were cleaned from surrounding tissue and fixed/decalcified in Richard-Allan Scientific Cal-Rite fixative (Thermo Scientific), followed by paraffin embedding. Sections (3 μm) were used for immunohistological staining or H&E overview staining. For immunohistochemistry sections were de-paraffinized and re-hydrated in xylene and decreasing ethanol concentrations. Heat-mediated antigen retrieval was conducted by placing sections in blocking buffer (40 mM Tris and 1.2 mM EDTA in distilled water) in a microwave for 5 min at 330 W. Slides were left for cooling and rinsed with water. Nearly dried samples were circled with a PAP pen (Kisker) and incubated with blocking solution (1% BSA/PBS) for 60 min at room temperature. Primary antibodies, diluted in 1% BSA/PBS, were added and samples were incubated in a humidified chamber at 4°C overnight. Sections were washed with PBS three times. Secondary antibody and DAPI nucleus staining were applied for 10 min at room temperature in the dark. Samples were washed twice with PBS. To reduce auto-fluorescence 0.3% Sudan Black solution (in 70% EtOH) was applied for 20 min. Sections were washed three times and mounted with Fluoromount G (eBioscience, GER). Samples were stored at 4°C in the dark before evaluation via fluorescence microscopy. For the quantification of the different bone-resident populations, bone marrow regions of 0.05 mm^2^ from bone sections were selected on fluorescence images. For immunocytochemistry, fixated cells in well plates were permeabilized with 0.1% Triton X-100 solution and blocked with 3% BSA in PBS. Antibodies were used as listed in the [Key Resources Table](#sec4.1){ref-type="sec"}. For nuclear staining specimen were treated with DAPI. Sections and cells were analyzed using a Keyence BZ-9000 (Biorevo) fluorescence microscope (for up to two fluorescences) or a Zeiss confocal laser scanning microscope (LSM) 700 (for three fluorescences).

### Sternal transplantation {#sec4.4.4}

Sorted cell populations (see [Figure S2](#mmc1){ref-type="supplementary-material"}L) from luciferase-expressing rep^AdiLuc^ or tdTomato-expressing rep^tdTom^ mice were subcutaneously injected at 1.5 × 10^4^ cells in a 50% matrigel suspension into the sternal area of B6-albino mice. Eight weeks after transplantation, engrafted tissues were excised, fixed, and histologically analyzed. Mice injected with cells from rep^Luc^ animals were additionally subjected to Luciferase imaging with an IVIS imaging system (Perkin Elmer) before sacrifice. To this end, animals were intraperitoneally injected with luciferin (150 mg/kg) and subsequently anesthetized. After 12 to 18 min, the animals were imaged. Image analysis was performed with Living Image 4.4 software (Xenogen).

### BrdU cell proliferation in vivo assay {#sec4.4.5}

For 24 hr experiments mice were i.p.-injected with a single dose of 100 mg BrdU/kg (Sigma Aldrich) diluted in sterile PBS. Mice receiving a SD or HFD for ten days were given BrdU via drinking water at a concentration of 0.5 mg/mL. Drinking water was refreshed every other day. For single-cell immunostaining approximately 2 × 10^3^ cells/mouse of each population of interest were double-sorted on glass coverslips pre-coated with a 5 μL drop of DMEM(low). Coverslips were incubated for 30 min, allowing cells to attach. Cells were fixed by gently adding 4% Histofix for 10 min and washed three times for 3 min with PBS. Permeabilization solution (0.2% saponin/PBS) was applied for 6 min. Washing solution (0.02% saponin/PBS) for 5 min was followed by administering DNA-denaturation solution (2 M HCl in 0.02% saponin/PBS) for 20 min at 37°C. Cells were washed for 5 min and blocked for 30 min with 2% BSA in washing solution. Incubation with anti-BrdU antibody (Cedarlane) in blocking solution was done overnight at 4°C. On the next day, three times washing for 10 min and incubation with Alexa Fluor 488 donkey anti-rat (FisherScientific) and DAPI staining in blocking solution for 30 min at room temperature in the dark was performed. Cells were washed with washing solution three times and PBS once. Coverslips were mounted with Fluoromount G (eBioscience). Samples were stored at 4°C in the dark before evaluation via fluorescence microscopy (Keyence). The percentage of BrdU-positive cells within each population was calculated as compared to total numbers of DAPI-positive cells.

### Competitive hematopoietic reconstitution assay {#sec4.4.6}

Animals were given antibiotics via drinking water and an analgetic one week and two days, repectively, before experiments. C57BL/6J recipient mice were lethally irradiated with a single dose of 7.5 Gy. For reconstitution assays, 150 LT-LSK cells from donor mice expressing the CD45.1 allele were mixed with 1 × 10^5^ freshly isolated whole bone marrow supporting cells (collected by flushing the BM from long bones) from C57BL/6J mice (CD45.2) in addition to 1.5 × 10^4^ cells of one of the investigated populations isolated from rep^dtom^ mice, then injected in the medullary cavity of the tibia through the proximal articular surface. For the investigation of acute effects peripheral blood, tibia bone marrow, and tibia bones were analyzed by flow cytometry five weeks post irradiation. For long-term experiments blood was taken every four weeks and tibia bone marrow and tibia bones were analyzed 16 weeks post irradiation. Red blood cells were lysed, followed by antibody staining to distinguish between different blood cell populations (as listed in the [Key Resources Table](#sec4.1){ref-type="sec"}). For evaluation of donor chimerism the frequency of donor fraction (CD45.1^+^:CD45.2^-^) was calculated.

### Fracture model {#sec4.4.7}

Mice were given an analgetic (MediGel, ClearH~2~O) starting two days prior to surgery. Anesthetized mice were injected with 1.5 × 10^4^ cells in a 50% matrigel suspension through the proximal articular surface of the tibia. A steel pin (diameter 0.35 mm) was inserted into the medullary cavity for stabilization and a fracture was induced with scissors 0.5 cm distal from the knee. At the indicated time point after fracture induction, tibiae were harvested for analyses. After removal of the pin from extracted tibiae, μCT analysis was conducted with LaTheta LCT-200 (Hitachi-Aloka) using manufacturer's pre-defined parameters for isolated bone measurements. Alternatively, tibiae were fixed and decalcified followed by paraffin embedding and sectioning at 3 μm per slice. Samples were stained using SafraninO/Fast green and Movat Pentachrome. ImageJ software was used for computer-assisted histomorphometric analysis of fracture calluses. Six representative sections of each callus were analyzed for bone, fibrous, and cartilaginous tissue areas in a blinded manner. For DPP4 in vivo experiments mice received a daily dose of PBS, Diprotin A (5 mg/kg body weight; Sigma) or Sitagliptin (10 mg/kg body weight; biomol) i.p. for 9 consecutive days. For fracture healing experiments application started two days before induction of injury/cell injection. Fracture healing was assessed one day after the last DPP4-inhibitor administration.

### Capture, Library Preparation, and Sequencing of cell population {#sec4.4.8}

A total of 17,000 CD45^-^CD31^-^Sca1^-^Zfp423^+^, 50,000 CD45^-^CD31^-^Sca1^+^CD24^-^, 5,000 CD45^-^CD31^-^Sca1^+^CD24^+^ and 30,000 CD45^-^CD31^-^Sca1^-^Pα^+^ cells were FAC-sorted from bones of 4 mice (the 3 biological replicates were done on 3 different days), collected in a 1.5 mL Eppendorf tube containing 50 μL RLT Plus Buffer (QIAGEN) supplemented with 1% 2-Mercaptoethanol, immediately frozen in dry-ice and kept at −80°C. The time elapsed between mouse euthanasia and the termination of the FACS procedure was ∼400 min. RNA extraction, reverse transcription and cDNA pre-amplification, Nextera XT libraries and sequencing of the cell populations was done as previously described and according to the manufacturer\'s instructions. Briefly, RNA was extracted using the RNeasy Plus Micro Kit (QIAGEN), together with genomic DNA eliminator (QIAGEN). Reverse transcription and cDNA pre-amplification were performed using the SMARTer PCR cDNA Synthesis kit (Clontech) and the Advantage 2 PCR kit (Clontech). cDNA was harvested and quantified with the Bioanalyzer DNA High-Sensitivity kit (Agilent Technologies). Libraries were prepared using the Nextera XT DNA Sample Preparation Kit and the Nextera Index Kit (Illumina). Multiplexed libraries were pooled, and paired-end 100-bp sequencing was performed on one flow--cell (two lanes) of an Illumina HiSeq 2500.

### RNA-seq data processing and analysis {#sec4.4.9}

Sequencing data were aligned to the *Mus musculus* genome (Ensembl version 38.82) using GSNAP (version 2014-10-07) with default parameters. HTseq-count was used to count the number of reads mapped to each gene (default options). Almost all libraries showed good quality, with sizes ranging between 2-3.5x10^7^ read counts and a fraction of reads mapped to exons greater than 75% ([Figure S7](#mmc1){ref-type="supplementary-material"}). One library yielded less than 300 reads and was excluded from downstream analysis. The data was normalized for sequencing depth using size factors. The union of the top 1,000 genes expressed in each library was selected, which resulted in a list of 2,120 genes. Principal component analysis was carried out on the standardized log10-transformed normalized counts (after adding a pseudo-count of 1 to avoid infinities). Hierarchical clustering analysis was performed using Euclidean distances with Ward's method on the same dataset. Differentially expressed genes between groups of libraries were identified by using the bioconductor R-package DESeq2 library at a FDR of 0.1. Genes that were not detected in any library were removed prior to the analysis and possibly confounding factors were taken into account (i.e., the animal each sample was taken from). RNA-seq data was statistically analyzed using the R-statistical package and Paleontological Statistics (PAST, version 3.10, <http://folk.uio.no/ohammer/past/>, accessed December 2015). For DE analyses, gene expression was compared between all investigated cell populations. A p-value of \< 0.05 was used as a cut-off for differentially expressed genes. Heat-maps contain representative top-regulated genes, which were further divided by known cell type specific functions as previously described in the literature and unknown novel marker genes.

### Gene expression analysis {#sec4.4.10}

Total RNA isolation and gene expression analysis was conducted using standard methods as described before ([@bib43]) using column-based RNA-isolation, reverse transcription for cDNA synthesis, and SYBR green-based detection during quantified real-time PCR. Primer sequences were used as noted in the [Key Resources Table](#sec4.1){ref-type="sec"}.

Quantification and Statistical Analyses {#sec4.5}
---------------------------------------

All data are presented as mean ± standard error of the mean (SEM). The sample size for each experiment and the replicate number of experiments are included in the figure legends. Statistical significance was defined as p \< 0.05. Statistical analyses were performed using unpaired, two-tailed Student's t test or Mann-Whitney-U-test where applicable for comparison between two groups, and an ANOVA test was used for experiments involving more than two groups (GraphPad Prism; version 6.04).

Data and Software Availability {#sec4.6}
------------------------------

### Data Resources {#sec4.6.1}

The accession number for the gene expression data generated by RNA-seq data reported in this study is ENA: ERP013883 (<http://www.ebi.ac.uk/ena>).
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